News | Coronavirus (COVID-19) | July 02, 2020

Fujifilm Sonosite and EMF Partner in the Battle Against COVID-19

Industry leaders to research the growing importance of point-of-care ultrasound in COVID-19 care

Industry leaders to research the growing importance of point-of-care ultrasound in COVID-19 care

July 2, 2020 —Fujifilm Sonosite, Inc. and the Emergency Medicine Foundation (EMF), a 501(c)(3) nonprofit organization founded by the American College of Emergency Physicians (ACEP), announced its partnership on the EMF COVID-19 Research Grant program. To support this program, Fujifilm Sonosite is contributing a $90,000 research grant and soon to be released Sonosite PX point-of-care ultrasound (POCUS) systems.

The COVID-19 pandemic has affected 188 countries, with over 10 million confirmed cases and 500,000 deaths as of July 2020. More research is critically needed to understand the pathophysiology of COVID-19 and how to manage patients for improved outcomes and reduced mortality rates. The goal of the EMF's COVID-19 grant is to conduct research with the participation of emergency medicine physicians, and to provide high-impact, new knowledge to advance emergency patient care, improve response of healthcare EMS systems, and protect emergency medicine healthcare professionals during pandemics. 

"From an early stage in this pandemic, we learned how frontline emergency physicians were using point of care ultrasound to assess this deadly illness. Despite their remarkable progress, we recognized more research was required as unfortunately the pandemic continues to grow," said Diku Mandavia, M.D., FACEP, Senior Vice President, Chief Medical Officer of Fujifilm Sonosite. "We're proud to collaborate with ACEP and EMF in a time when we are still learning more about this disease and how to best care for patients. As a powerful and portable imaging modality that provides critical answers at the bedside, we believe point-of-care ultrasound can be integrated into more COVID-19 care pathways."

"We are grateful to have FUJIFILM Sonosite's support to further investigate the role ultrasound plays in this catastrophic disease," said David Wilcox, M.D., FACEP, Chair of the EMF Board of Trustees. "For the industry to truly overcome COVID-19 and prepare for future pandemics, we must more specifically understand how diagnostic imaging innovations may improve the quality of care, as well as patient and staff safety."

The Fujifilm Sonosite COVID-19 Point-of-Care Ultrasound Acceleration Research Grant is currently open and accepting proposals from interested emergency physicians until August 21, 2020. Grant winners will be announced in September 2020 and recognized at the 2020 ACEP Research Forum. Selected grant winners will be invited to present their research findings at the ACEP21 Scientific Assembly scheduled to take place in October 2021 in Boston, Massachusetts.

For more information: www.emfoundation.org/apply

 

Related Content

Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Carestream Health will offer insights on technology, innovative new products and research in medical imaging through a new webinar series titled Carestream Talks. #RSNA20
News | Radiology Education | October 14, 2020
October 14, 2020 — Carestrea
The use of CT and X-ray in the assessment and treatment plan for President Trump underscores the critical role that medical imaging must play in the fight against COVID-19

A COVID-19 chest CT heat map from RADlogics

News | Artificial Intelligence | October 13, 2020
October 13, 2020 — Given recent high-profile cases of...